ERBB2 and breast carcinoma: For example, evidence has linked miR-21 to trastuzumab resistance (an anti-HER2 antibody) in HER2 + BC, topotecan resistance (a topoisomerase inhibitor) in MCF-7 cells, as well as taxol resistance (a microtubule stabilizer) in breast carcinoma cells [54,140,141].